Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib Maintenance in Advanced TNBC
NCT07321015Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jan 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib in triple-negative breast cancer (TNBC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Jan 2026; status: recruiting.
02
Drugs
fluzoparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07321015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07321015.